MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

XL041

CAS No. : 1256918-39-4

MCE 站：XL041

产品活性：XL041 (BMS-852927) 是一种 LXRβ 选择性激动剂。

研究领域：Metabolic Enzyme/Protease

作用靶点：LXR

In Vitro: XL041 (BMS-852927) is an LXRβ-selective agonist with 20% LXRα ａnd 88% LXRβ activity compared to a full pan agonist in transactivation assays. XL041 is potent, with an EC₅₀=9 nM ａnd 26% activity in an in vitro human whole-blood endogenous target gene activation assay (WBA). BMS-852927 has similar binding affinity to LXRα ａnd LXRβ (19 ａnd 12 nM, respectively).

In Vivo: XL041 (BMS-852927), has a very favorable profile at efficacious doses in cynomolgus monkeys ａnd mice. XL041 pre-treatment of C57BL/6J mice for 7 days results in potent, dose-dependent stimulation of cholesterol efflux in this system, reaching a maximum in the 3 mg/kg/day dose group of 70% above vehicle in the initial efflux rate. Similar results are obtained in LDLR knockout (KO) mice. In a separate study, XL041 inhibits the progression of atherosclerosis in a 12 week study in LDLR KO mice. Importantly, the dose response for inhibition of atherosclerosis (0.1-3 mg/kg/day) is similar to the dose response for macrophage reverse cholesterol transport (RCT) stimulation (0.03-3 mg/kg/day), a major underlying mechanism through which LXR agonists affect the disease.

相关产品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Metabolism/Protease Compound Library  |  Clinical Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  T0901317  |  GSK2033  |  LXR-623  |  27-Hydroxycholesterol  |  (20S)-Protopanaxatriol  |  SR9243  |  SR9238  |  24-Hydroxycholesterol  |  AZ876  |  Saikosaponin A  |  Yamogenin  |  Nagilactone B  |  DMHCA  |  Gymnestrogenin  |  Iristectorigenin B  |  LXRβ agonist-2

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。